Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–79
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Has given written informed consent before any study-related activity is performed
Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon® is intended to be used for treatment
Age greater than or equal to 18 years and less than 80 years
Advanced hormone-dependent prostate cancer without any other clinically significant disorder
Easten Cooperative Oncology Group score ≤ 2
PSA ≥ 2 ng/mL at screening
Life expectancy of at least 12 months as per the investigator's judgement
You may not be if
Previous or concurrent hormonal management of prostate cancer
Contraindication for prescription of Firmagon®
Concurrent treatment with a 5-α-reductase inhibitor
Considered as a candidate for curative therapy
History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema
QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications
Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin
Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment)
Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer
Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections
